SecBot SecBot

PHVS drug pipeline

Pharvaris N.V. · 1 rated drug
$32.44
−2.8% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 mixed
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhaseFiled/PDUFA (IR capsule); Phase 3 (XR tablet)
Time to marketIR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.

deucrictibant Updated Jul 6

What to watch

Two binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.

Bull case
  • RAPIDe-3 Phase 3 data was robust, met all primary and 11 secondary endpoints with high statistical significance (p<0.0001), including median symptom relief in 1.28 hours and complete resolution in 11.95 hours, positioning it as a potentially best-in-class oral option.
  • If approved, deucrictibant would be the first oral bradykinin B2 receptor antagonist for HAE, a novel mechanism versus sebetralstat's kallikrein inhibition, potentially offering differentiation in efficacy or tolerability.
  • The prophylactic XR formulation addresses a larger commercial market than on-demand treatment alone; Phase 2 CHAPTER-1 data showed 84.5% reduction in monthly attack rates, and the CHAPTER-3 readout (Q3 2026) could open that opportunity.
Bear case
  • KalVista's sebetralstat (EKTERLY) was FDA-approved in July 2025 as the first oral on-demand HAE therapy, a full ~2 years ahead of deucrictibant's April 2027 PDUFA, giving it a massive head start in brand awareness, physician adoption, and formulary access.
  • The FDA previously placed a clinical hold on deucrictibant in 2022 over preclinical safety concerns (since resolved), but the history introduces residual regulatory risk.
  • CHAPTER-3 topline results (Q3 2026) are a binary binary event, if the XR formulation fails to meet endpoints, the prophylactic opportunity collapses and the stock would likely re-rate sharply lower.

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
deucrictibantStudy of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEPhase 3Completed85Jul 21, 2026
Deucrictibant low doseDose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type IIPhase 2Terminated · results34Jun 30, 2025